Bullfrog AI | 10-Q: FY2025 Q3 Revenue: USD 83.41 K

Revenue: As of FY2025 Q3, the actual value is USD 83.41 K.

EPS: As of FY2025 Q3, the actual value is USD -0.15.

EBIT: As of FY2025 Q3, the actual value is USD -1.588 M.

Collaboration Revenue: $83,413 for the three months ended September 30, 2025, and $116,670 for the nine months ended September 30, 2025, compared to $0 for the same periods in 2024.

Net Loss: - $1,551,612 for the three months ended September 30, 2025, compared to - $1,763,464 for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $5,017,894 compared to - $5,278,904 for the same period in 2024.
Gross Profit: $15,370 for the three months ended September 30, 2025, and $21,892 for the nine months ended September 30, 2025, compared to $0 for the same periods in 2024.
Operating Expenses: $1,585,053 for the three months ended September 30, 2025, compared to $1,819,941 for the same period in 2024. For the nine months ended September 30, 2025, operating expenses were $5,117,868 compared to $5,467,622 for the same period in 2024.
Research and Development: $345,992 for the three months ended September 30, 2025, compared to $566,584 for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses were $1,402,549 compared to $1,632,409 for the same period in 2024.
General and Administrative: $1,239,061 for the three months ended September 30, 2025, compared to $1,253,357 for the same period in 2024. For the nine months ended September 30, 2025, general and administrative expenses were $3,715,319 compared to $3,835,213 for the same period in 2024.

Operating Cash Flow: - $4,337,270 for the nine months ended September 30, 2025, compared to - $4,338,214 for the same period in 2024.
Financing Cash Flow: $996,999 for the nine months ended September 30, 2025, compared to $5,952,472 for the same period in 2024.

Core Business Focus: The company aims to generate revenues through strategic relationships with biopharma companies, structured as a combination of fees in cash, equity in partners, or other consideration and intellectual property. The objective is to uncover valuable insights to reduce the risk and increase the speed of the drug development process.
Non-Core Business: The company plans to acquire the rights to drugs at various stages of development and use its proprietary AI/ML technology to advance the development of such drugs, with the objective of creating near-term value and then exiting and monetizing as quickly as possible, preferably within approximately 30 months.
Priority: The company anticipates securing additional capital through revenues from licensing agreements and collaborative arrangements within its operating business and/or the selling of equity securities or entry into debt transactions.